Sustained delivery of dibutyryl cyclic adenosine monophosphate to the transected spinal cord via oligo [(polyethylene glycol) fumarate] hydrogels

Gemma E. Rooney, Andrew M. Knight, Nicolas N. Madigan, Louann Gross, Bingkun Chen, Catalina Vallejo Giraldo, Seungmae Seo, Jarred J. Nesbitt, Mahrokh Dadsetan, Michael J Yaszemski, Anthony John Windebank

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

This study describes the use of oligo [(polyethylene glycol) fumarate] (OPF) hydrogel scaffolds as vehicles for sustained delivery of dibutyryl cyclic adenosine monophosphate (dbcAMP) to the transected spinal cord. dbcAMP was encapsulated in poly(lactic-co-glycolic acid) (PLGA) microspheres, which were embedded within the scaffolds architecture. Functionality of the released dbcAMP was assessed using neurite outgrowth assays in PC12 cells and by delivery to the transected spinal cord within OPF seven channel scaffolds, which had been loaded with Schwann cells or mesenchymal stem cells (MSCs). Our results showed that encapsulation of dbcAMP in microspheres lead to prolonged release and continued functionality in vitro. These microspheres were then successfully incorporated into OPF scaffolds and implanted in the transected thoracic spinal cord. Sustained delivery of dbcAMP inhibited axonal regeneration in the presence of Schwann cells but rescued MSC-induced inhibition of axonal regeneration. dbcAMP was also shown to reduce capillary formation in the presence of MSCs, which was coupled with significant functional improvements. Our findings demonstrate the feasibility of incorporating PLGA microsphere technology for spinal cord transection studies. It represents a novel sustained delivery mechanism within the transected spinal cord and provides a platform for potential delivery of other therapeutic agents.

Original languageEnglish (US)
Pages (from-to)1287-1302
Number of pages16
JournalTissue Engineering - Part A
Volume17
Issue number9-10
DOIs
StatePublished - May 1 2011

Fingerprint

Fumarates
Hydrogels
Cyclic AMP
Polyethylene glycols
Spinal Cord
Microspheres
Scaffolds
Stem cells
Mesenchymal Stromal Cells
Schwann Cells
Regeneration
Cells
Acids
Hydrogel
PC12 Cells
Spinal Cord Injuries
Encapsulation
Assays
Thorax
Technology

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Biomedical Engineering
  • Biomaterials
  • Medicine(all)

Cite this

Sustained delivery of dibutyryl cyclic adenosine monophosphate to the transected spinal cord via oligo [(polyethylene glycol) fumarate] hydrogels. / Rooney, Gemma E.; Knight, Andrew M.; Madigan, Nicolas N.; Gross, Louann; Chen, Bingkun; Giraldo, Catalina Vallejo; Seo, Seungmae; Nesbitt, Jarred J.; Dadsetan, Mahrokh; Yaszemski, Michael J; Windebank, Anthony John.

In: Tissue Engineering - Part A, Vol. 17, No. 9-10, 01.05.2011, p. 1287-1302.

Research output: Contribution to journalArticle

Rooney, Gemma E. ; Knight, Andrew M. ; Madigan, Nicolas N. ; Gross, Louann ; Chen, Bingkun ; Giraldo, Catalina Vallejo ; Seo, Seungmae ; Nesbitt, Jarred J. ; Dadsetan, Mahrokh ; Yaszemski, Michael J ; Windebank, Anthony John. / Sustained delivery of dibutyryl cyclic adenosine monophosphate to the transected spinal cord via oligo [(polyethylene glycol) fumarate] hydrogels. In: Tissue Engineering - Part A. 2011 ; Vol. 17, No. 9-10. pp. 1287-1302.
@article{4e2713f3f06e4194a4c5c049b60fb40b,
title = "Sustained delivery of dibutyryl cyclic adenosine monophosphate to the transected spinal cord via oligo [(polyethylene glycol) fumarate] hydrogels",
abstract = "This study describes the use of oligo [(polyethylene glycol) fumarate] (OPF) hydrogel scaffolds as vehicles for sustained delivery of dibutyryl cyclic adenosine monophosphate (dbcAMP) to the transected spinal cord. dbcAMP was encapsulated in poly(lactic-co-glycolic acid) (PLGA) microspheres, which were embedded within the scaffolds architecture. Functionality of the released dbcAMP was assessed using neurite outgrowth assays in PC12 cells and by delivery to the transected spinal cord within OPF seven channel scaffolds, which had been loaded with Schwann cells or mesenchymal stem cells (MSCs). Our results showed that encapsulation of dbcAMP in microspheres lead to prolonged release and continued functionality in vitro. These microspheres were then successfully incorporated into OPF scaffolds and implanted in the transected thoracic spinal cord. Sustained delivery of dbcAMP inhibited axonal regeneration in the presence of Schwann cells but rescued MSC-induced inhibition of axonal regeneration. dbcAMP was also shown to reduce capillary formation in the presence of MSCs, which was coupled with significant functional improvements. Our findings demonstrate the feasibility of incorporating PLGA microsphere technology for spinal cord transection studies. It represents a novel sustained delivery mechanism within the transected spinal cord and provides a platform for potential delivery of other therapeutic agents.",
author = "Rooney, {Gemma E.} and Knight, {Andrew M.} and Madigan, {Nicolas N.} and Louann Gross and Bingkun Chen and Giraldo, {Catalina Vallejo} and Seungmae Seo and Nesbitt, {Jarred J.} and Mahrokh Dadsetan and Yaszemski, {Michael J} and Windebank, {Anthony John}",
year = "2011",
month = "5",
day = "1",
doi = "10.1089/ten.tea.2010.0396",
language = "English (US)",
volume = "17",
pages = "1287--1302",
journal = "Tissue Engineering - Part A",
issn = "1937-3341",
publisher = "Mary Ann Liebert Inc.",
number = "9-10",

}

TY - JOUR

T1 - Sustained delivery of dibutyryl cyclic adenosine monophosphate to the transected spinal cord via oligo [(polyethylene glycol) fumarate] hydrogels

AU - Rooney, Gemma E.

AU - Knight, Andrew M.

AU - Madigan, Nicolas N.

AU - Gross, Louann

AU - Chen, Bingkun

AU - Giraldo, Catalina Vallejo

AU - Seo, Seungmae

AU - Nesbitt, Jarred J.

AU - Dadsetan, Mahrokh

AU - Yaszemski, Michael J

AU - Windebank, Anthony John

PY - 2011/5/1

Y1 - 2011/5/1

N2 - This study describes the use of oligo [(polyethylene glycol) fumarate] (OPF) hydrogel scaffolds as vehicles for sustained delivery of dibutyryl cyclic adenosine monophosphate (dbcAMP) to the transected spinal cord. dbcAMP was encapsulated in poly(lactic-co-glycolic acid) (PLGA) microspheres, which were embedded within the scaffolds architecture. Functionality of the released dbcAMP was assessed using neurite outgrowth assays in PC12 cells and by delivery to the transected spinal cord within OPF seven channel scaffolds, which had been loaded with Schwann cells or mesenchymal stem cells (MSCs). Our results showed that encapsulation of dbcAMP in microspheres lead to prolonged release and continued functionality in vitro. These microspheres were then successfully incorporated into OPF scaffolds and implanted in the transected thoracic spinal cord. Sustained delivery of dbcAMP inhibited axonal regeneration in the presence of Schwann cells but rescued MSC-induced inhibition of axonal regeneration. dbcAMP was also shown to reduce capillary formation in the presence of MSCs, which was coupled with significant functional improvements. Our findings demonstrate the feasibility of incorporating PLGA microsphere technology for spinal cord transection studies. It represents a novel sustained delivery mechanism within the transected spinal cord and provides a platform for potential delivery of other therapeutic agents.

AB - This study describes the use of oligo [(polyethylene glycol) fumarate] (OPF) hydrogel scaffolds as vehicles for sustained delivery of dibutyryl cyclic adenosine monophosphate (dbcAMP) to the transected spinal cord. dbcAMP was encapsulated in poly(lactic-co-glycolic acid) (PLGA) microspheres, which were embedded within the scaffolds architecture. Functionality of the released dbcAMP was assessed using neurite outgrowth assays in PC12 cells and by delivery to the transected spinal cord within OPF seven channel scaffolds, which had been loaded with Schwann cells or mesenchymal stem cells (MSCs). Our results showed that encapsulation of dbcAMP in microspheres lead to prolonged release and continued functionality in vitro. These microspheres were then successfully incorporated into OPF scaffolds and implanted in the transected thoracic spinal cord. Sustained delivery of dbcAMP inhibited axonal regeneration in the presence of Schwann cells but rescued MSC-induced inhibition of axonal regeneration. dbcAMP was also shown to reduce capillary formation in the presence of MSCs, which was coupled with significant functional improvements. Our findings demonstrate the feasibility of incorporating PLGA microsphere technology for spinal cord transection studies. It represents a novel sustained delivery mechanism within the transected spinal cord and provides a platform for potential delivery of other therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=79955022803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955022803&partnerID=8YFLogxK

U2 - 10.1089/ten.tea.2010.0396

DO - 10.1089/ten.tea.2010.0396

M3 - Article

C2 - 21198413

AN - SCOPUS:79955022803

VL - 17

SP - 1287

EP - 1302

JO - Tissue Engineering - Part A

JF - Tissue Engineering - Part A

SN - 1937-3341

IS - 9-10

ER -